Cardiac rehabilitation referral, attendance and mortality in women

Jillian D Colbert1, Billie-Jean Martin2, Mark J Haykowsky3

  • 1Libin Cardiovascular Institute, University of Calgary, Canada.

Insights

Women with coronary artery disease (CAD) benefit significantly from cardiac rehabilitation (CR), experiencing greater mortality reduction than men. Despite lower referral and completion rates, CR participation improves survival for women with CAD.

Area of Science:

  • Cardiology
  • Public Health
  • Health Services Research

Background:

  • Cardiac rehabilitation (CR) is proven to reduce mortality in patients with coronary artery disease (CAD).
  • Existing research indicates potential sex-based disparities in healthcare utilization and outcomes.
  • Understanding these differences is crucial for optimizing cardiovascular disease management.

Purpose of the Study:

  • To investigate sex-based differences in long-term mortality among a large cohort of patients with CAD.
  • To analyze referral and attendance patterns for CR stratified by sex.
  • To determine the impact of CR referral and completion on mortality in women compared to men.

Main Methods:

  • Retrospective cohort study utilizing data from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) and Cardiac Wellness Institute of Calgary (CWIC).
  • Comparison of CR referral and attendance rates between men and women.
  • Logistic regression to predict CR referral and completion by sex.
  • Cox proportional hazard models to assess the association between CR participation and survival, stratified by sex.

Main Results:

  • A total of 25,958 patients with CAD were included, with women comprising 24.6%.
  • Women had significantly lower rates of CR referral (31.1% vs. 42.2%) and completion (50.1% vs. 60.4%) compared to men.
  • After adjusting for covariates, women showed significantly lower odds of CR referral (aOR 0.74) and completion (aOR 0.73).
  • Women who completed CR experienced a greater mortality reduction (HR 0.36) than men (HR 0.51), indicating a comparatively greater relative benefit.

Conclusions:

  • This large cohort study is the first to demonstrate a significant mortality reduction associated with CR referral and attendance in women with CAD.
  • Women derive a comparatively greater survival benefit from participating in CR than men.
  • Findings highlight the need to address disparities in CR access and encourage participation among women to improve cardiovascular outcomes.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
743
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
514
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
476
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
591
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
1.2K